Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated braf pathway
INTERNA TECHNOLOGIES BV;KONINKLIJKE NEDERLANDSE AKADEMIE VAN WETENSCHAPPEN
发明人:
BEREZIKOV EUGENE,POELL JOS BERNARD,GOMMANS WILLEMIJN MARIA,VAN HAASTERT RICK JAN,VAN PUIJENBROEK ANDREAS ALPHONS FRANCISCUS LUDOVICUS,SCHAAPVELD ROELAND QUIRINUS JOZEF,PREVOST GRÉGOIRE PIERRE ANDRÉ
申请号：
NZ70432211
公开号：
NZ704322A
申请日:
2011.07.01
申请国别(地区):
NZ
年份:
2016
代理人:
摘要：
Disclosed is the use of a miRNA-193a molecule, a miRNA molecule from 6 to 30 nucleotides in length comprising at least 6 of the nucleotides present in seed sequence SEQ ID NO: 188 or 189 and/or having at least 70% identity with SEQ ID NO:127 or 128, an isomiR, or a source thereof or a composition comprising said miRNA, isomiR, or source thereof in the manufacture of a medicament for preventing, treating, regressing, curing and/or delaying a disease or a condition associated with melanoma and/or a disease or a condition associated with activated BRAF pathway, wherein the sequences are as defined in the complete specification. Also disclosed is a method for identification of a substance capable of preventing, treating, regressing, curing and/or delaying melanoma or a condition or disease associated with melanoma and/or a disease or a condition associated with activated BRAF pathway in a subject, the method comprising the steps of: (a) providing an in vitro or ex vivo test cell population capable of expressing a miRNA molecule, an isomiR or sources thereof as disclosed above, preferably the test population comprises melanoma cells, or cells with activated BRAF pathway； (b) contacting or incubating the test cell population with the substance； (c) determining the expression level of said miRNA molecule or isomiR thereof or the activity or steady state level of said miRNA molecule or isomiR thereof in the test cell population contacted or incubated with the substance； (d) comparing the expression, activity or steady state level determined in (c) with the expression, activity or steady state level of said miRNA molecule or isomer in a test cell population that is not contacted with the substance； and, (e) identifying a substance that produces a difference in expression level, activity or steady state level of said miRNA molecule or isomiR, between the test cell population that is contacted with the substance and the test cell population that is not contacted with the subst
